The company's full imaging services for pre-market clinical trials and post-market surveillance are now available on the artificial intelligence (AI)-enabled cloud-based platform, according to Astute. As a result, medical technology companies can now use AI software and Astute's image-guided therapy platform to track the performance of their devices before and after regulatory approval, in line with new regulatory requirements for implantable devices, the vendor said.